公开(公告)号：US5516801A

公开(公告)日：1996-05-14

申请号：US365171

申请日：1994-12-28

Applicant: David F. Horrobin ,  Brenda E. Reynolds

Inventor： David F. Horrobin ,  Brenda E. Reynolds

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: Prevention and/or treatment of abnormal calcification in any tissue by the administration of (i) GLA and/or its EFA metabolites, and in particular the rapidly produced DGLA and/or (ii) EPA and/or its precursors, stearidonic acid and 20:4 n-3, and metabolites, docosahexaenoic acid (DHA) or docosapenmenoic acid (22:5 n-3), as such or in salt or other pharmacologically acceptable form. This is especially suitable for prevention or treatment of nephrocalcinosis and/or renal stones.

Abstract translation: 通过施用（i）GLA和/或其EFA代谢物，特别是快速产生的DGLA和/或（ii）EPA和/或其前体，十八碳四烯酸和20 ：4 n-3，以及代谢物，二十二碳六烯酸（DHA）或二十二碳二烯酸（22：5 n-3），或盐或其他药理学上可接受的形式。 这特别适用于预防或治疗肾钙质沉着症和/或肾结石。

公开(公告)号：US5466841A

公开(公告)日：1995-11-14

申请号：US187042

申请日：1994-01-27

Applicant: David F. Horrobin ,  Austin McMordie ,  Mehar S. Manku

Inventor： David F. Horrobin ,  Austin McMordie ,  Mehar S. Manku

IPC: A23J7/00 ,  A61K8/00 ,  A61K8/55 ,  A61K8/58 ,  A61K8/96 ,  A61K38/00 ,  A61Q19/00 ,  C07F9/10 ,  C07F9/113 ,  C07F9/117 ,  C07F9/02

CPC classification number: A61K8/553 ,  A23J7/00 ,  A61Q19/00 ,  C07F9/10 ,  C07F9/117

Abstract: A phospholipid comprising two different unsaturated fatty acids, the fatty acids being selected from the twelve n-6 and n-3 essential fatty acids, oleic acid, parinaric acid and combinic acid.

Abstract translation: 包含两种不同不饱和脂肪酸的磷脂，所述脂肪酸选自十二个n-6和n-3必需脂肪酸，油酸，对苯二酸和组合酸。

公开(公告)号：US5380757A

公开(公告)日：1995-01-10

申请号：US61110

申请日：1993-05-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K9/02 ,  A61K9/06 ,  A61K9/107 ,  A61K31/20 ,  A61K31/202 ,  A61P13/02 ,  A61P15/00

CPC classification number: A61K31/20

Abstract: Gamma-linolenic (GLA) and/or dihomo-gamma-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.

Abstract translation: γ-亚麻酸（GLA）和/或二氢-γ-亚麻酸（DGLA）可用于治疗外阴营养不良和/或阴道干燥。 n-6或n-3系列的其他必需脂肪酸也可以与GLA和/或DGLA结合使用。

公开(公告)号：US5223271A

公开(公告)日：1993-06-29

申请号：US765008

申请日：1991-09-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K9/06 ,  A61K31/17 ,  A61K31/19 ,  A61K31/20 ,  A61K31/202 ,  A61K31/505 ,  A61K31/60 ,  A61K31/63 ,  A61K33/00 ,  A61K33/14 ,  A61K47/20 ,  A61P17/00 ,  A61P31/12 ,  A61P43/00 ,  C01D3/04 ,  C01D7/00 ,  C07C55/10 ,  C07C57/12 ,  C07D239/557

CPC classification number: A61K9/0014 ,  A61K31/19 ,  A61K31/20 ,  A61K31/505 ,  A61K31/60 ,  A61K31/63 ,  A61K33/00 ,  A61K33/14 ,  A61K47/20

Abstract: The present invention provides a method of treatment and/or prophylaxis of the human or animal body to combat Molluscum Contagiosum, said treatment comprising topically administering a therapeutically or prophylactically effective amount of a physiologically acceptable lithium compound to affected areas on said body.It also extends to pharmaceutical compositions comprising a physiologically acceptable lithium compound together with at least one keratolytic and/or skin penetration assisting agent and at least one pharmaceutically acceptable carrier or excipient.

公开(公告)号：US5128152A

公开(公告)日：1992-07-07

申请号：US711104

申请日：1991-06-03

Applicant: David F. Horrobin ,  Michel E. Begin

Inventor： David F. Horrobin ,  Michel E. Begin

IPC: A61K31/19 ,  A61K31/20 ,  A61K31/23 ,  A61K31/295 ,  A61K33/26 ,  A61P35/00

CPC classification number: A61K31/20 ,  A61K31/23 ,  A61K33/26

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract translation: 一种或多种n-6或n-3必需脂肪酸，特别是γ-亚麻酸，二氢-γ-亚麻酸或二十碳五烯酸和可同化铁化合物的药学上可接受的组合物以剂量单位形式任选地含有稀释剂或载体 所述酸以本身的形式存在或作为在体内可转化为衍生物的衍生物，所述酸或衍生物的量为1mg至100g（以γ-亚麻酸计算）和所述铁化合物0.1mg至10g（以 铁）或所述量的次数便于日常给药。

公开(公告)号：US4965075A

公开(公告)日：1990-10-23

申请号：US273680

申请日：1988-11-21

Applicant: David F. Horrobin ,  Stephen C. Cunnane ,  Mehar S. Manku

Inventor： David F. Horrobin ,  Stephen C. Cunnane ,  Mehar S. Manku

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61K31/30 ,  A61K33/34 ,  A61P3/06 ,  A61P7/02 ,  A61P9/00 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/18 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K33/34 ,  Y10S514/866

Abstract: Methods of influencing the 1-series/2-series PG balance in the body by administering a composition containing .gamma.-linolenic acid and/or dihomo-.gamma.-linolenic acid and assimilable copper compounds optionally with a diluent or carrier, the acids being as such or as derivatives convertible in the body thereto. The amounts of the acids or derivatives are 0.2 to 10 g (calculated as .gamma.-linolenic acid) and of copper compounds are 0.1 to 100 mg (calculated as copper).

Abstract translation: 通过施用含有γ-亚麻酸和/或二 - γ-亚麻酸的组合物和任选地与稀释剂或载体同化的铜化合物来影响体内1系/ 2系PG平衡的方法，酸如此 或作为在体内可转换的衍生物。 酸或衍生物的量为0.2〜10g（以γ-亚麻酸计算），铜化合物的量为0.1〜100mg（以铜计）。

公开(公告)号：US4758592A

公开(公告)日：1988-07-19

申请号：US911719

申请日：1986-09-26

Applicant: David F. Horrobin ,  Robert A. Casper

Inventor： David F. Horrobin ,  Robert A. Casper

IPC: A61K31/16 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61P43/00 ,  A61K31/22

CPC classification number: A61K31/16 ,  A61K31/20 ,  A61K31/23

Abstract: Method of prevention or treatment of endometriosis wherein effective amounts of one or both of (i) gamma-linolenic acid and/or dihomo-gamma-linolenic acid and (ii) 18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3 or 22:6 n-3) are administered against endometriosis as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.

Abstract translation: 预防或治疗子宫内膜异位症的方法，其中有效量的（i）γ-亚麻酸和/或二 - γ-亚麻酸和（ii）18：4n-3和/或一种或多种代谢物中的一种或两种 18：4 n-3（20：4 n-3,20：5 n-3,22：5 n-3或22：6 n-3）与子宫内膜异位症一起施用或以酯的形式施用， 盐，酰胺或其它可衍生于体内的衍生物，单独或在可接受的药物载体或稀释剂中。

公开(公告)号：US4666701A

公开(公告)日：1987-05-19

申请号：US839228

申请日：1986-03-13

Applicant: David F. Horrobin ,  Mehar S. Manku ,  Yung S. Huang

Inventor： David F. Horrobin ,  Mehar S. Manku ,  Yung S. Huang

IPC: A61K31/00 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61P1/00 ,  A61P1/04 ,  A61P29/00 ,  A61K27/00

CPC classification number: A61K31/20 ,  A61K31/23 ,  Y10S514/922

Abstract: Gamma-linolenic acid or dihomo-gamma-linolenic acid for use in the reduction or prevention of gastro-intestinal bleeding and other side effects shown by NSAIDs when administered on a continuing basis, including use in allowing said administration to be replaced by administration of said acid alone in arthritis and other conditions without exacerbation of symptoms.

Abstract translation: 用于减少或预防胃肠道出血的γ-亚麻酸或二 - 亚麻酸，以及NSAIDs持续施用时所显示的其它副作用，包括用于允许所述给药被施用所述 酸单独在关节炎等条件下无症状加重。

公开(公告)号：US4328243A

公开(公告)日：1982-05-04

申请号：US251901

申请日：1981-04-07

Applicant: David F. Horrobin ,  Julian Lieb

Inventor： David F. Horrobin ,  Julian Lieb

IPC: A61K31/20 ,  A61K33/00 ,  C07C57/03

CPC classification number: C07C57/03 ,  A61K31/20 ,  A61K33/00

Abstract: A method for the treatment and/or prophylaxis of the side-effects of lithium treatment in a subject suffering from manic-depressive psychosis, which method comprises administering to the subject an effective amount therefor of dihomogamma-linolenic acid and/or a biosynthetic precursor thereof.

Abstract translation: 一种用于治疗和/或预防患有躁狂抑郁精神病的受试者的锂处理的副作用的方法，该方法包括向受试者施用有效量的二羟基亚麻酸和/或其生物合成前体 。

公开(公告)号：US5763484A

公开(公告)日：1998-06-09

申请号：US823790

申请日：1997-03-24

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A23D9/00 ,  A23L1/30 ,  A23L1/325 ,  A23L1/48 ,  A61K31/16 ,  A61K31/20 ,  A61K31/22 ,  A61K31/23 ,  A61K31/557 ,  A61K35/56 ,  A61K35/60 ,  A61K36/00 ,  A61K36/185 ,  A61K38/00 ,  A61P3/08 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/30 ,  A61P27/16 ,  A61P35/00 ,  A61P37/08

CPC classification number: A61K35/60 ,  A23D9/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/557 ,  A61K36/185 ,  Y10S514/861 ,  Y10S514/866

Abstract: A method of treatment of a disorder, including breast cancer and other cancer, with effective amounts of one or more of the metabolites of linoleic acid (GLA, DGLA, AA, 22:4n-y or 22:5n-6) and one or more of the metabolites of .alpha.-linolenic acid (18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3 or 22:6n-3) administered as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto alone or in acceptable pharmaceutical carrier or diluent.

Abstract translation: 一种治疗包括乳腺癌和其他癌症的病症的方法，其有效量的一种或多种亚油酸代谢物（GLA，DGLA，AA，22：4n-y或22：5n-6）和一种或多种 更多的如此给予的α-亚麻酸（18：4n-3,20：4n-3,20：5n-3,22：5n-3或22：6n-3）的代谢物或酯的形式 ，盐，酰胺或其它可在体内转化为其的衍生物，或在可接受的药物载体或稀释剂中。